Provided by Tiger Fintech (Singapore) Pte. Ltd.

Blueprint Medicines

84.69
+2.583.14%
Post-market: 84.69-0.0200-0.02%16:42 EDT
Volume:634.40K
Turnover:53.18M
Market Cap:5.41B
PE:-79.35
High:84.97
Open:82.16
Low:81.19
Close:82.11
Loading ...

Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (ABT) and Blueprint Medicines (BPMC)

TIPRANKS
·
Yesterday

Blueprint Medicines Price Target Maintained With a $128.00/Share by Wedbush

Dow Jones
·
16 Apr

Adma Biologics (ADMA) Moves 7.8% Higher: Will This Strength Last?

Zacks
·
15 Apr

Blueprint Medicines: Strong Growth Potential Driven by Ayvakit and Promising Pipeline

TIPRANKS
·
08 Apr

Blueprint Medicines Corp : Morgan Stanley Assumes Coverage With Equal Weight Rating; Price Target $100 VS $120

THOMSON REUTERS
·
20 Mar

Balanced Outlook on Blueprint Medicines: Growth Prospects and Market Dynamics

TIPRANKS
·
20 Mar

Blueprint Medicines assumed with an Equal Weight at Morgan Stanley

TIPRANKS
·
20 Mar

Reddit initiated, Netflix upgraded: Wall Street’s top analyst calls

TipRanks
·
18 Mar

Wolfe Research Initiates Blueprint Medicines at Outperform With $132 Price Target

MT Newswires Live
·
18 Mar

Blueprint Medicines initiated with an Outperform at Wolfe Research

TIPRANKS
·
18 Mar

Exploring High Growth Tech Stocks In The US Market March 2025

Simply Wall St.
·
13 Mar

Have Blueprint Medicines Insiders Been Selling Stock?

Simply Wall St.
·
09 Mar

Blueprint Medicines Initiated at Sector Outperform by Scotiabank

Dow Jones
·
08 Mar

Is Blueprint Medicines (NASDAQ:BPMC) A Risky Investment?

Simply Wall St.
·
07 Mar

Blueprint Medicines: Hold Rating Amid Concerns Over Ayvakit’s Liver Function Test Elevations

TIPRANKS
·
05 Mar

Blueprint Medicines Price Target Maintained With a $125.00/Share by Citizens Capital Markets

Dow Jones
·
03 Mar

Analysts Offer Insights on Healthcare Companies: Pharvaris (PHVS) and Blueprint Medicines (BPMC)

TIPRANKS
·
03 Mar

Blueprint Medicines Highlights Leading Portfolio of Mast Cell-Targeted Therapies at 2025 AAAAI / WAO Joint Congress

PR Newswire
·
28 Feb

Blueprint Medicines Corporation (BPMC): Among the Oversold Biotech Stocks to Buy Now

Insider Monkey
·
25 Feb

RIGL Stock Surges 41.4% in a Year: Time to Buy or Sell?

Zacks
·
24 Feb